{"id":7933,"date":"2025-07-16T15:13:11","date_gmt":"2025-07-16T12:13:11","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7933"},"modified":"2025-07-16T15:13:11","modified_gmt":"2025-07-16T12:13:11","slug":"fda-approval-of-finerenone-kerendia-for-expanded-heart-failure-indications-july-14-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/fda-approval-of-finerenone-kerendia-for-expanded-heart-failure-indications-july-14-2025\/","title":{"rendered":"FDA Approval of Finerenone (Kerendia) for Expanded Heart Failure Indications \u2013 July 14. 2025"},"content":{"rendered":"<div>FDA Approval of Finerenone (Kerendia) for Expanded Heart Failure Indications \u2013 July 14. 2025<\/div>\n<div><\/div>\n<div><span> 1. Drug &amp; Manufacturer:<\/span><\/div>\n<div><span> \u2022 Finerenone (Kerendia)<\/span><\/div>\n<div><span> \u2022 Developed by Bayer<\/span><\/div>\n<div><span> \u2022 A non-steroidal mineralocorticoid receptor antagonist (MRA)<\/span><\/div>\n<div><span> 2. New FDA Approval:<\/span><\/div>\n<div><span> \u2022 Approved to treat heart failure patients with LVEF \u2265 40%<\/span><\/div>\n<div><span> \u2022 Includes:<\/span><\/div>\n<div><span> \u2022 HFmrEF (Heart Failure with mildly reduced Ejection Fraction)<\/span><\/div>\n<div><span> \u2022 HFpEF (Heart Failure with preserved Ejection Fraction)<\/span><\/div>\n<div><span> \u2022 Previously approved for patients with CKD + Type 2 Diabetes<\/span><\/div>\n<div><\/div>\n<div><span> 3. Expanded Eligibility:<\/span><\/div>\n<div><span> \u2022 Now approved for HF patients without CKD or T2D<\/span><\/div>\n<div><span> \u2022 Significantly broadens the eligible treatment population<\/span><\/div>\n<div><span> 4. Supporting Evidence:<\/span><\/div>\n<div><span> \u2022 Based on results from FINEARTS-HF, a Phase III, Bayer-sponsored trial<\/span><\/div>\n<div><span> \u2022 Demonstrated improved outcomes in HFmrEF and HFpEF populations<\/span><\/div>\n<div><span> \u2022 Reduced hospitalization and cardiovascular death rates<\/span><\/div>\n<div><span> 5. Unmet Need Addressed:<\/span><\/div>\n<div><span> \u2022 Despite current therapies:<\/span><\/div>\n<div><span> \u2022 21% of symptomatic HF patients progress to hospitalization or CV death<\/span><\/div>\n<div><span> \u2022 25% of hospitalized patients are readmitted within one year<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.bayer.com\/en\/us\/news-stories\/fda-approves-kerendia\"><span> https:\/\/www.bayer.com\/en\/us\/news-stories\/fda-approves-kerendia<\/span><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approval of Finerenone (Kerendia) for Expanded Heart Failure Indications \u2013 July 14. 2025 1. Drug &amp; Manufacturer: \u2022 Finerenone (Kerendia) \u2022 Developed by Bayer \u2022 A non-steroidal mineralocorticoid receptor antagonist (MRA) 2. New FDA Approval: \u2022 Approved to treat heart failure patients with LVEF \u2265 40% \u2022 Includes: \u2022 HFmrEF (Heart Failure with mildly [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-7933","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7933"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7933\/revisions"}],"predecessor-version":[{"id":7934,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7933\/revisions\/7934"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}